Market revenue in 2020 | USD 108.1 million |
Market revenue in 2028 | USD 258.6 million |
Growth rate | 11.5% (CAGR from 2020 to 2028) |
Largest segment | Lymphoma |
Fastest growing segment | Lymphoma |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Leukemia, Lymphoma, MPNs, Other Cancers |
Key market players worldwide | Roche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.
Lymphoma was the largest segment with a revenue share of 46.16% in 2020. Horizon Databook has segmented the Japan hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.
Japan's hemato oncology market accounted for largest market share in 2021 and is anticipated to hold dominant position over the forecast period. High prevalence of blood cancer, increasing healthcare infrastructure, and rising healthcare awareness are major driving factors that contribute to market growth.
According to data published by Globocan 2020, around 13,667 new cases of leukemia, 33,000 new cases of non-Hodgkin lymphoma, and 1,723 new cases of Hodgkin lymphoma were estimated to be diagnosed in the country.
The same source states that around 9,842, 15,218, and 224 people died from leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma, respectively, in Japan. Furthermore, an increase in approval and commercialization of tests in Japan, along with favorable insurance coverage, is likely to drive the market over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into Japan hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account